Clinical Trials Listing Service

Obesity

Last updated: July 6, 2023
Sponsor: Eli Lilly and Company
Overall Status: Active - Recruiting

Phase

3

Condition

Obesity

Treatment

N/A

Clinical Study ID

TX310394
  • Ages 18-100
  • All Genders

Study Summary

Effect of LY3502970 Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participant must be 18 years of age or older.
  • Have a clinical diagnosis of type 2 Diabetes
  • Are on a stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening visit 1.

Exclusion

Exclusion Criteria:

  • Have type 1 Diabetes
  • Are currently planning treatment for or have diabetic retinopathy and/or macular edema requirement acute treatment.
  • Have a history of ≥1 episode of ketoacidosis or hyperosmolar state or coma.
  • Have a history of ≥1 episode of severe hypoglycemia or ≥1 episode of hypoglycemia unawareness within the last 6 months.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • Condition: Obesity
  • Clinical Trial Identifier: NCT49895719
  • Sponsor: Eli Lilly and Company
  • Looking for participates within a 30-mile radius of site location.

Connect with a study center

  • AMR Fort Myers

    Fort Myers, Florida 33912
    United States

    Active - Recruiting

  • AMR Fort Myers

    Fort Myers, Florida 33912
    United States

    Active - Recruiting

  • Clinical Physiology Associates

    Fort Myers, United States 33912

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.